16 June 2021
19 May 2021
IntegraGen is delighted to share this new publication on tumor plasticity and cisplatin resistance in pediatric liver cancers. Sequencing services (WES, RNA-seq, snRNA-seq, RRBS) and expertise support, particularly for single nuclei RNA-seq experiment, (…) »
15 March 2021
As provider of the whole genome sequencing, IntegraGen is proud of sharing this new publication.Background
Urinary tract infections (UTIs) are caused by an uropathogenic strain of Escherichia coli that produce colibactin, a bacterial genotoxin.Results
In the study (…) »
03 March 2021
As provider of the bulk and single-cell RNA-seq libraries and sequencing, IntegraGen is proud of sharing this new publication.Background
Duchenne Muscular Dystrophy (DMD) is a rare disease characterized by early muscular damages. The (…) »
12 January 2021
IntegraGen reports 2020 revenue of €9.0 million, an increase of +10%, and a cash position of €5.0 million as of December 31, 2020
IntegraGen announced today its unaudited business figures for the year 2020.2020 revenue amounted to 9.0 M € versus 8.1 M € in 2019, an increase of 10% over 12 months. Increased sequencing services reported for company’s Evry lab and at outsourced platforms run by the company for the SeqOIA (…) »
09 October 2020
Analysis of circulating tumor DNA (ctDNA) offers great opportunities for cancer research and patient care. There are multiple applications and benefits associated with studying ctDNA including the ability to identify tumor heterogeneity and the detection of somatic mutations unidentified following (…) »
18 September 2020
IntegraGen has announced today its financial results for the first half of 2020 with the accounts having been reviewed by the Board of Directors on 17 September 2020.
Company posts positive operating performance (EBITDA) for the second consecutive semester, supported by revenue growth (+5%) and confirms (…) »
16 September 2020
COMMUNIQUE PROVIDING THE INFORMATION NOTE AND THE DOCUMENT “OTHER INFORMATION RELATING TO CHARACTERISTICS, IN PARTICULAR LEGAL, FINANCIAL AND ACCOUNTING” OF THE COMPANY ONCODNA S.A.
This press release was prepared and distributed by OncoDNA S.A. in accordance with the provisions of Articles 231-27 1 ° and 2 ° and 231-28 of the general regulations of the Autorité des marchés financiers (the “AMF”).
01 September 2020
09 July 2020
Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN to acquire all outstanding shares at a price of 2.20€ per share. This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of (…) »